[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355635-105":59,"doc-detail-355635-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","the-farnesyl-transferase-inhibitor-darlifarnib-ko-2806-resensitizes-relapsing-tumors-to-ras-inhibition","The Farnesyl Transferase Inhibitor Darlifarnib (KO-2806) Resensitizes Relapsing Tumors to RAS Inhibition","","Resistance remains a key barrier limiting clinical benefit from RAS-targeting therapies, prompting combination approaches. The study identifies persistent mTORC1 activity in preclinical KRAS-mutant non-small cell lung cancer and colorectal cancer models as a frequent, nongenetic driver of inherent and adaptive resistance to RAS inhibition. This vulnerability is targetable using the farnesyl transferase inhibitor darlifarnib (KO-2806), which blocks mTORC1 activation via RHEB while sparing mTORC2 to reduce toxicities. Adding KO-2806 to tumors progressing on mutant-selective RAS inhibitors yields rapid, durable regression and rescues sensitivity to pan-RAS inhibition.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-farnesyl-transferase-inhibitor-darlifarnib-ko-2806-resensitizes-relapsing-tumors-to-ras-inhibition/355635/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-farnesyl-transferase-inhibitor-darlifarnib-ko-2806-resensitizes-relapsing-tumors-to-ras-inhibition/355635.png","ImageObject",300,407,{"name":92,"@type":93},"นรินทร์","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the study focus on regarding RAS inhibition?","Question",{"text":112,"@type":113},"Resistance limits the clinical benefit of RAS-targeting therapeutic agents and most responses are restricted in duration, motivating combination strategies.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does KO-2806 act in the context of RAS inhibition resistance?",{"text":117,"@type":113},"KO-2806 is a farnesyl transferase inhibitor that blocks mTORC1 activation via RHEB while sparing mTORC2 to limit associated toxicities.",{"name":119,"@type":110,"acceptedAnswer":120},"What is the study’s key finding about tumor response to adding KO-2806?",{"text":121,"@type":113},"In KRAS-mutant NSCLC and colorectal cancer models progressing on mutant-selective RAS inhibitors, adding KO-2806 drives rapid and durable tumor regression, and it can rescue sensitivity to a pan-RAS inhibitor.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},355635,1790559024,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336475104957,"https://ap-avatar.wpscdn.com/avatar/22000c4c6bd8a5076e1?x-image-process=image/resize,m_fixed,w_180,h_180&k=1787554080175789136","The Farnesyl Transferase Inhibitor Darlifarnib (KO-2806) Resensitizes Relapsing Tumors to RAS Inhibition  \nHetika Vora Patel, Alison Elizabeth Smith, Stacia Chan, Jovylyn Gatchalian Gasendo, Ayuna Jombik, John Edward Greer, Tejas Samantaray, Linda Kessler, Amitava Mitra, Xuefeng Zhu, Yahu A. Liu, Francis Burrows, and Shivani Malik  \n|  |  | A |  | B | S |  | T | R |  | A |  | C | T |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  | Resistance remains a key issue limiting the clinical benefit from RAS-targeting therapeutic agents and necessitates combination approaches. In this study, we identified persistent mTORC1 activity in preclinical KRAS-mutant non–small cell lung cancer (NSCLC) and colorectal cancer models as a frequent, nongenetic driver of inherent and adaptive resistance to RAS inhibition. This vulnerability was targetable with the farnesyl transferase inhibitor darlifarnib (KO-2806), which blocks mTORC1 activation via RHEB while sparing mTORC2 to limit associated toxicities. The addition of KO-2806 to NSCLC or colorectal cancer tumors progressing on mutant-selective RAS inhibitors led to rapid and durable tumor regression. In contrast, switching from mutantselective to pan-RAS inhibitor monotherapy resulted in only\u003Cbr>􀀶 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | stasis of NSCLC tumors and had no effect on colorectal cancer tumor progression. Furthermore, the addition of KO-2806 rescued sensitivity of progressing tumors to the pan-RAS inhibitor RMC-6236 . These results establish mTORC1 as an important mediator of escape from RAS inhibition and highlight KO-2806 as a promising RAS companion inhibitor in patients with prior RAS inhibitor exposure.\u003Cbr>Significance: KO-2806 salvages RAS inhibitor activity by controlling parallel mTORC1 in RAS inhibitor-resistant tumors in which vertical inhibition of MAPK is insufficient to restore sensitivity, providing a combination strategy for resistant patients. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n\nIntroduction  \nThe approval of KRASG12C inhibitors and ongoing clinical development of additional mutant-selective and pan-RAS targeted agents have heralded a shift in the treatment paradigm for patients with RAS-mutant tumors (1–4) . Nevertheless, only a subset of these patients responds to RAS inhibitor therapy, and most responses are limited in duration (5) . This limitation has led to a flurry of proposed combination strategies to mitigate resistance, many of which center around targeting nodes upstream or downstream of oncogenic KRAS to inhibit pathway output more potently (5–7) .  \nIn preclinical models of non–small cell lung cancer (NSCLC), it has been demonstrated that the degree of inhibition of mTORC1 correlates with responsiveness to KRASG12C-targeted agents, and inhibitors of KRASG12C and mTOR are synergistic (8) . Moreover, mutations that cooccur with KRAS, like STK11 in NSCLC and PIK3CA in colorectal cancer, are thought to limit KRASG12C inhibitor efficacy, point","cbCaipZZ1rDSh5vL","https://ap.wps.com/l/cbCaipZZ1rDSh5vL","pdf",8456409,13,"English","# Introduction\n## Rationale for combination strategies in RAS-mutant tumors\n## Role of mTORC1 and resistance mechanisms\n## Hypothesis for KO-2806 with RAS inhibitors","[{\"question\":\"What problem does the study focus on regarding RAS inhibition?\",\"answer\":\"Resistance limits the clinical benefit of RAS-targeting therapeutic agents and most responses are restricted in duration, motivating combination strategies.\"},{\"question\":\"How does KO-2806 act in the context of RAS inhibition resistance?\",\"answer\":\"KO-2806 is a farnesyl transferase inhibitor that blocks mTORC1 activation via RHEB while sparing mTORC2 to limit associated toxicities.\"},{\"question\":\"What is the study’s key finding about tumor response to adding KO-2806?\",\"answer\":\"In KRAS-mutant NSCLC and colorectal cancer models progressing on mutant-selective RAS inhibitors, adding KO-2806 drives rapid and durable tumor regression, and it can rescue sensitivity to a pan-RAS inhibitor.\"}]","The Farnesyl Transferase Inhibitor Darlifarnib (KO-2806) Resensitizes Relapsing Tumors to RAS Inhibition | PDF",1790120247,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/30ccaeca03bc1ea05b2980d923e9e81d.webp",983,1315,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/20b8a6a5a5962cdfb14e79e4a4fddccc.webp",982,1314,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/97ea90313634f48877730613278b9dc2.webp",981,1312,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/462ef662e3bd4b44d77efd9042115f83.webp",980,1311]